[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Sarepta Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2216555822.png) @Sarepta Sarepta Therapeutics

Sarepta Therapeutics posts on X about arrowhead the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::2216555822/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:interactions.svg)

- X Week XXXXXX +2,401%
- X Month XXXXXX +38%
- X Months XXXXXX +6,846%
- X Year XXXXXX -XX%

### Mentions: XX [#](/creator/twitter::2216555822/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:posts_active.svg)


### Followers: XXXXX [#](/creator/twitter::2216555822/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:followers.svg)

- X Week XXXXX +2.20%
- X Month XXXXX +3.40%
- X Months XXXXX +7%
- X Year XXXXX +12%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::2216555822/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::2216555822/influence)
---

**Social topic influence**
[arrowhead](/topic/arrowhead)
### Top Social Posts [#](/creator/twitter::2216555822/posts)
---
Top posts by engagements in the last XX hours

"News: The U.S. FDA granted Platform Technology Designation to SRP-9003 Sareptas investigational gene therapy for the treatment of LGMD type 2E/R4. This is one of the first programs to receive the technology designation. Read more at"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1930272306384793816) 2025-06-04 14:35:55 UTC 6159 followers, 7949 engagements


"Today we announced that enrollment & dosing is complete in Study SRP-9003-301 a Phase X multi-national open-label study of investigational candidate SRP-9003 for the treatment of LGMD2E/R4. Data are expected in the first half of 2025"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1869376529836503101) 2024-12-18 13:37:50 UTC 6156 followers, 3310 engagements


"Today we shared updates from our clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5 2D/R3 and 2E/R4. Read more here:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1912122376738779536) 2025-04-15 12:34:34 UTC 6153 followers, 3401 engagements


"On this #RareDiseaseDay were excited to announce the launch of Route XX The Duchenne Scholarship Program. Were awarding up to XX scholarships to individuals living with Duchenne and up to X scholarships to siblings. Learn more:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1895475979042369781) 2025-02-28 14:07:44 UTC 6156 followers, 1169 engagements


"Excited to be a partner of the 2025 @MDAorg Clinical & Scientific Conference. Well be there celebrating XX years of #MDA impact & sharing updates on how Sarepta is advancing science for Duchenne and LGMD patients. #MDAconference"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1900643260193784031) 2025-03-14 20:20:40 UTC 6154 followers, 2760 engagements


"Attending #ASGCT2025 Explore our posters and oral presentations. Learn more here:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1923409078182683050) 2025-05-16 16:03:54 UTC 6154 followers, 1550 engagements


"CEO Doug Ingram on Sareptas global licensing and collaboration agreement with Arrowhead Pharmaceuticals and how the agreement will help solidify Sareptas position as a genetic medicine leader"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1861418651364082108) 2024-11-26 14:36:04 UTC 6144 followers, 1802 engagements


"Today we released our financial results for Q4 and the full year of 2024 showing a XX% increase in net product revenue over the same quarter of the prior year. Our president and CEO on the results:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1894884362237186122) 2025-02-26 22:56:51 UTC 6142 followers, 1543 engagements